Tsukamoto Taku, Kiyota Miki, Kawata Eri, Uoshima Nobuhiko, Tatekawa Shotaro, Chinen Yoshiaki, Nagoshi Hisao, Mizutani Shinsuke, Shimura Yuji, Yamamoto-Sugitani Mio, Kobayashi Tsutomu, Horiike Shigeo, Yasukawa Satoru, Yanagisawa Akio, Taniwaki Masafumi, Kuroda Junya
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Department of Hematology, Matsushita Memorial Hospital, Osaka, Japan.
Int J Hematol. 2017 May;105(5):658-667. doi: 10.1007/s12185-016-2166-0. Epub 2016 Dec 19.
Disease-specific cytogenetic abnormalities involving BCL2 gene rearrangement frequently co-exist with other cytogenetic abnormalities, contributing to disease progression in follicular lymphoma (FL). In the present study, we retrospectively investigated the prognostic impact of BCL2-unrelated cytogenetic abnormalities in FL. Of 139 consecutively diagnosed patients with FL at two independent institutes, metaphase spreads of tumor cells were obtained for use in G-banding analysis in 77 patients. The recurrent additional cytogenetic abnormalities included chromosome gains +5 (n = 8), +7 (n = 16), +12 (n = 10), and +X (n = 12), and losses -8 (n = 7), -13 (n = 12) -15 (n = 7), and 6q- (n = 7). While -15 was associated with shorter progression-free survival (PFS) in all 77 analyzed patients with evaluable G-banding results (p = 0.04), this negative impact was not evident in 42 patients treated using an R-CHOP-like regimen as first-line treatment. By contrast, 6q- was predictive for shorter PFS in patients who were initially treated with R-CHOP-like regimens without maintenance therapy (p < 0.01), while this negative impact was not evident in all 77 patients with evaluable G-banding results. These results suggest the presence of a molecular region in chromosome 6q that is responsible for the shorter PFS following R-CHOP-like chemotherapy.
涉及BCL2基因重排的疾病特异性细胞遗传学异常常与其他细胞遗传学异常共存，这促进了滤泡性淋巴瘤（FL）的疾病进展。在本研究中，我们回顾性研究了FL中与BCL2无关的细胞遗传学异常的预后影响。在两个独立机构连续诊断的139例FL患者中，77例患者获得了肿瘤细胞的中期染色体铺片用于G显带分析。复发性额外细胞遗传学异常包括染色体增加 +5（n = 8）、+7（n = 16）、+12（n = 10）和 +X（n = 12），以及染色体丢失 -8（n = 7）、-13（n = 12）、-15（n = 7）和6q-（n = 7）。虽然在所有77例具有可评估G显带结果的分析患者中，-15与无进展生存期（PFS）缩短相关（p = 0.04），但在42例使用R-CHOP样方案作为一线治疗的患者中，这种负面影响并不明显。相比之下，6q-在最初接受R-CHOP样方案治疗且未进行维持治疗的患者中预测PFS较短（p < 0.01），而在所有77例具有可评估G显带结果的患者中，这种负面影响并不明显。这些结果表明，6号染色体上存在一个分子区域，该区域导致R-CHOP样化疗后PFS缩短。
